1. Home
  2. MKTW vs CELU Comparison

MKTW vs CELU Comparison

Compare MKTW & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MarketWise Inc.

MKTW

MarketWise Inc.

HOLD

Current Price

$16.38

Market Cap

39.1M

Sector

Technology

ML Signal

HOLD

Logo Celularity Inc.

CELU

Celularity Inc.

HOLD

Current Price

$1.24

Market Cap

34.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MKTW
CELU
Founded
1999
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.1M
34.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MKTW
CELU
Price
$16.38
$1.24
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
$20.00
$6.00
AVG Volume (30 Days)
8.5K
44.8K
Earning Date
02-27-2026
11-14-2025
Dividend Yield
4.87%
N/A
EPS Growth
N/A
N/A
EPS
2.55
N/A
Revenue
$342,206,000.00
$40,578,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$76.00
P/E Ratio
$6.44
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.08
$1.00
52 Week High
$21.74
$4.35

Technical Indicators

Market Signals
Indicator
MKTW
CELU
Relative Strength Index (RSI) 56.42 40.81
Support Level $16.37 $1.22
Resistance Level $16.28 $1.32
Average True Range (ATR) 0.51 0.08
MACD 0.10 0.01
Stochastic Oscillator 70.00 18.94

Price Performance

Historical Comparison
MKTW
CELU

About MKTW MarketWise Inc.

Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms including mobile, desktops, and tablets.

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Share on Social Networks: